Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425004 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib for Patients With Recurrent or Progressive Meningioma
A Phase 2 study of Meningioma, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT05425004: Recruiting Phase 2 study of Meningioma, sponsored by Baptist Health South Florida.
NCT05425004 is a Phase 2 study of Meningioma that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 24 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05425004, a Phase 2 study of Meningioma, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Primary Outcome
PFS is defined as the proportion of participants who from the start of treatment are free from objective tumor progression or death from any cause at 6 months. Tumor response and progression will be assessed using Response Assessment in Neuro-Oncology (RANO) meningioma criteria. Progressive disease (PD) is defined as the presence of any of the following criteria: ≥ 25% increase in target lesion area relative to nadir, unequivocal progression of any nontarget lesion, presence of new lesions, or w
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (3)
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
What NCT05425004 shows while recruiting
NCT05425004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT05425004 reports a single indexed study location in Florida, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05425004 about?
NCT05425004 is a clinical study titled "Cabozantinib for Patients With Recurrent or Progressive Meningioma". A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
What is the current status of trial NCT05425004?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-06-01. Estimated completion is 2028-05.
What conditions does trial NCT05425004 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT05425004?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05425004?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05425004 being conducted?
This trial has 3 study locations across Florida, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05425004's enrollment target sits among peer trials
24 16th of 21 higher than 6 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI